Skip to main content
Premium Trial:

Request an Annual Quote

Miragen Issued Notice of Allowance for microRNA-Related IP

Premium

Miragen Therapeutics this week announced that it has received a notice of allowance from the US Patent and Trademark Office for a patent application covering microRNAs that modulate smooth muscle proliferation and differentiation.

Specifically, the intellectual property claims methods of use in modulating miR-143, which the company said plays a critical role in controlling smooth muscle cells at the site of vascular injury.

Studies conducted by Miragen with collaborators at the University of Texas Southwestern Medical Center in a carotid artery ligation model demonstrated that “injection of synthetic mimics of miR-143 stopped blood vessel blockage by inhibiting stenosis at the site of vessel injury,” Miragen said.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.